NEWS
China’s NMPA approves authorization of commercialization for Oravig®
China’s NMPA has granted the approval of commercialization for Oravig®
Happy New Year!
In 2021, Vectans Pharma will offer new therapeutic perspectives based on Lauriad® technology.
LORAMYC® 50 mg: BfArM grants a 3-year exemption from the sunset clause
The BfArM granted a 3-year exemption of the sunset clause for LORAMYC® 50 mg.
Exclusive licensing agreement with m8 Pharmaceuticals
m8 Pharmaceuticals and Vectans Pharma signed an exclusive licensing agreement of Loramyc® (miconazole Lauriad®) for Mexico and Brazil.
Jonathan Cohen promoted Director of Regulatory and Industrial Affairs
” It has been almost a year since Jonathan joined Vectans pharma team. Over the past few months, his professional…
Meeting on ORAVI® /LORAMYC® with Sosei Heptares and FujiFilm Pharma
Vectans Pharma participated to the Commemorative Lecture for new release of ORAVI®/LORAMYC® Mucoadhesive Tablet 50mg, a meeting organized by Sosei…
Vectans Pharma launches an innovative medecine for treating herpes labialis
About 1 in 10 people suffer from recurring herpes labialis in France. Patients have an average of 3,4 episodes each…
Vectans Pharma will be attending
Les Entretiens de Bichat
Vectans Pharma will meet Health Care Professionnals during Les Entretiens de Bichat on 8 & 9 October 2018 in Issy-les-Moulineaux.
Dr Stefan Lempereur appointed as Chief Medical Officer
Vectans Pharma announces the appointment of Dr Stefan Lempereur as its new Chief Medical Officer, effective from March 1st 2018.
